Analyst Research Report Snapshot

Title:

ASTRAZENECA - MISPLACED FEARS?

Price:

$10.00

Provider:

Edison Investment Research

Date:

29 Jan 2010

Pages:

2

Type:

AcrobatPDF

Companies referenced:

AZN.L

Available for Immediate Download
Summary:

AstraZeneca’s FY09 operational performance showed it was able to benefit from the opportunities created by the shortage in supply of generic Toprol XL and the swine flu vaccine, while also decreasing its working capital by $1.3bn. However, its shares trade at a considerable discount to its peers (FY09 P/E of 7.4x vs 12.5x) because of exaggerated concerns about the patent cliff. The five-year guidance suggests that revenues could be 15% higher than 2014 consensus forecasts. FOR MORE INFORMATION ON THE ATTACHED RESEARCH PLEASE CALL 020 3077 5700, EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.